Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is an
antiangiogenic treatment currently proposed to recurrent high grade glioma patients.
Unfortunately some patients fail to respond to this treatment and finding biological factors
allowing the discrimination between potential responders and non responders would be very
helpful. As the immune system plays a key role in angiogenesis induction and maintenance in
cancer, it could serve as a surrogate marker of angiogenesis in cancer patients.
The purpose of this study is to determine the influence of bevacizumab treatment on
circulating immune cells in high grade glioma patients and to search for a link between the
variation of these cells and the response to treatment.